Guggenheim Reiterates Abivax (ABVX) at Buy, 'ABVX remains as our Best Idea'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $175.00 price target on Abivax (NASDAQ: ABVX).The analyst commented: "Yesterday, we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
